FDA, EMA reviewing IV formulation of Merck's Noxafil

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an NDA for an IV formulation of antifungal agent Noxafil posaconazole. The pharma declined to disclose the PDUFA date or wh...